Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways

Author(s): Elisa Molinelli*, Anna Campanati, Valerio Brisigotti, Annamaria Offidani .

Journal Name: Current Pharmaceutical Biotechnology

Volume 18 , Issue 12 , 2017

Abstract:

Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.

Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).

Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.

Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.

Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 12
Year: 2017
Page: [964 - 978]
Pages: 15
DOI: 10.2174/1389201019666180103140643
Price: $58

Article Metrics

PDF: 70
HTML: 3
EPUB: 1